Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals Inc. (LXRX) delivers innovative genomic-driven therapies for chronic diseases through its proprietary drug discovery platform. This page provides centralized access to official press releases, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and industry observers will find timely updates on key initiatives including neuropathic pain treatment LX9211, diabetes therapies, and cardiovascular research. The resource aggregates regulatory milestones, partnership announcements, and scientific presentations while maintaining strict compliance with financial disclosure standards.
All content undergoes verification against primary sources to ensure accuracy. Users can monitor developments across Lexicon's pipeline – from preclinical research to commercialized products like INPEFA® – through curated news streams free of promotional language.
Bookmark this page for efficient tracking of LXRX's progress in advancing non-opioid pain management solutions and targeted metabolic therapies. Regular updates provide critical insights into the company's position within the evolving biopharmaceutical landscape.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 12:30pm ET, and the 2024 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 17, at 8:35am ET.
Investors and interested parties can access live webcasts of these presentations through the 'Events' section of Lexicon's website at www.lexpharma.com/events. Recordings of the webcasts will remain available for two weeks following the original on-demand date, providing an opportunity for those unable to attend the live events to catch up on Lexicon's latest updates and strategic insights.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced new secondary analysis results from the Phase 3 SCORED trial for INPEFA® (sotagliflozin). The study showed that INPEFA reduced the risk of major adverse cardiovascular events (MACE) and heart failure (HF) events across all diabetes durations, with greater benefits for HF patients with longer diabetes duration.
Key findings include:
- INPEFA reduced primary endpoint events (5.6 vs 7.5 per 100 patient-years; HR: 0.74)
- MACE reduction: 4.8 vs 6.3 events per 100 patient-years (HR: 0.77)
- Increasing HF event reduction benefit with longer diabetes duration
- Results presented at the European Society of Cardiology Congress 2024
This analysis further differentiates INPEFA among SGLT inhibitors, highlighting its efficacy in reducing cardiovascular risks for heart failure patients, particularly those with longer diabetes duration.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that the FDA will hold an advisory committee meeting on October 31, 2024, to review Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). The PDUFA goal date remains December 20, 2024. The FDA plans to make background materials public two business days before the meeting. Lexicon's CEO, Dr. Mike Exton, expressed enthusiasm about sharing evidence supporting Zynquista's favorable benefit/risk profile for the target patient group.
Lexicon Pharmaceuticals announces strategic repositioning to optimize its commercial portfolio and drive growth. The company will focus on targeted promotion of INPEFA® for heart failure while preparing for the potential launch of ZYNQUISTA™ for type 1 diabetes with chronic kidney disease. This restructuring is expected to reduce 2025 operating costs by $40 million.
Key actions include:
- Reducing headcount by over 75 (50% of field force) by Q3 2024
- Targeted promotion of INPEFA® in heart failure
- Investment in ZYNQUISTA™ launch preparation
- Continued funding for R&D programs, including Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy and Phase 2b study of LX9211 in diabetic neuropathic pain
The company aims to create efficiencies while maintaining focus on high-impact opportunities for patients and shareholders.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced three poster presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists. The presentations focus on:
1. Efficacy and safety of sotagliflozin in patients with Type 1 Diabetes and Chronic Kidney Disease
2. Impact of sotagliflozin as an add-on to basal insulin-treated Type 2 Diabetes
3. Patient-reported burden of disease in Diabetic Peripheral Neuropathic Pain
Dr. Craig Granowitz, Lexicon's CMO, highlighted the importance of the data on sotagliflozin's clinical effect in people with T1D and CKD, noting their high risk of kidney failure and cardiovascular events due to poor glycemic control.
Lexicon Pharmaceuticals reported Q2 2024 financial results and provided a business update. Key highlights include:
- INPEFA (sotagliflozin) net sales of $1.6 million in Q2 2024
- Resubmitted NDA for ZYNQUISTA (sotagliflozin) in Type 1 Diabetes with PDUFA date of December 20, 2024
- Commenced SONATA Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy (HCM)
- Expect topline data in Q2 2025 from PROGRESS Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain
Financial results: Revenues increased to $1.6 million, R&D expenses rose to $17.6 million, and SG&A expenses increased to $39.2 million. Net loss was $53.4 million or $0.17 per share. Cash and investments stood at $310.0 million as of June 30, 2024.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming second quarter 2024 financial results conference call and webcast, scheduled for August 1, 2024, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) to discuss financial results and provide a business update.
Investors can access the call using the following details:
- U.S. Dial-in: (888) 317-6003
- International Dial-in: (412) 317-6061
- Conference ID: 7023126
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that the FDA has set a PDUFA goal date of December 20, 2024 for its resubmitted New Drug Application (NDA) for Zynquista™ (sotagliflozin). The drug is being evaluated as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This resubmission is considered a complete response to the FDA's 2019 action letter.
Lexicon is actively preparing for a potential launch in early 2025. If approved, Zynquista would mark Lexicon's second NDA approval and commercial launch in two years of products originating from their novel discovery platform. The company expressed confidence in sotagliflozin's favorable benefit/risk profile for the target patient population.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced new data highlighting potential cost-savings of INPEFA® (sotagliflozin) for heart failure treatment. A study published in the Journal of Managed Care + Specialty Pharmacy showed significant financial benefits for hospitals using INPEFA in alternative payment models (APMs). The analysis, based on the SOLOIST-WHF trial, demonstrated that INPEFA reduced hospital readmissions and emergency visits, leading to larger bonus payments under APMs.
Key findings include:
- $4,720 margin increase per admission for the Hospital Readmissions Reduction Program
- $1,200 margin increase for Bundled Payments for Care Improvement-Advanced program
- $1,078 margin increase for Medicare Shared Savings Program
These results align with two other peer-reviewed studies from June 2024, further supporting INPEFA's clinical and financial advantages in heart failure treatment.
Lexicon Pharmaceuticals announced the appointment of Mike Exton, Ph.D., as its new CEO, effective July 8, 2024. Dr. Exton succeeds Lonnel Coats, who retired on July 7, 2024. Exton brings extensive experience from his 14-year tenure at Novartis, where he led the global cardiometabolic therapeutic area and played a key role in commercializing the world’s leading heart failure drug. He also has a strong background in research, development, and strategic acquisitions. Concurrently, Jeff Wade has been promoted to president and COO, having served as Lexicon's president and CFO since October 2021.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
